Levetiracetam (UCB-L059) - Moligand™, 10mM in DMSO , Voltage-gated N-type calcium channel alpha-1B subunit blocker, CAS No.102767-28-2, Voltage-gated N-type calcium channel alpha-1B subunit blocker

CAS: 102767-28-2 Cat. No.: L408127 Molecular Weight: 170.21 EC Number: 600-348-9

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

SIB-S1 | (S)-2-(2-oxopyrrolidin-1-yl)butanamide

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Levetiracetam (UCB-L059) Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR) . Levetiracetam modulates the presynaptic P/Q-
In vitro

Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons.

In vivo

Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy.
Cell Data

cell lines：Jurkat, and HeLa

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

SIB-S1 | (S)-2-(2-oxopyrrolidin-1-yl)butanamide

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR). Levetiracetam modulates the presynaptic P/Q-type voltage-dependent calci

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR, MODULATOR

Mechanism of action

Voltage-gated N-type calcium channel alpha-1B subunit blocker

Product Properties

• ALogP: -0.3

Names and Identifiers

• Isomeric SMILES: CC[C@@H](C(=O)N)N1CCCC1=O
• WGK Germany: 3
• RTECS: UX9656166
• Molecular Weight: 170.21
• Reaxy-Rn: 1529106
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=1529106&ln=

Associated Targets(Human)

SV2A Tclin Synaptic vesicle glycoprotein 2A (2 Activities)

Discover Target: SV2A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Specific Rotation[α]: -88° (C=1,Acetone)
• Melt Point(°C): 118 °C

References

1. Kun Zhang, Jiahui Liang, Nadja R. Brun, Yanbin Zhao, Andreas A. Werdich.  (2021)  Rapid Zebrafish Behavioral Profiling Assay Accelerates the Identification of Environmental Neurodevelopmental Toxicants.  ENVIRONMENTAL SCIENCE & TECHNOLOGY,      [PMID:33470099] [10.1021/acs.est.0c06949]